Clinical case: Combined pulmonary fibrosis and emphysema with pulmonary hypertension - Clinical management

BMC Research Notes

Volumn 6, Issue SUPPL.1, 2013, Pages

  Cottin, Vincent ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; AZATHIOPRINE; PHENYLPROPIONIC ACID DERIVATIVE; PREDNISOLONE; PYRIDAZINE DERIVATIVE;

ARTICLE; CASE REPORT; DISEASE MANAGEMENT; HUMAN; LUNG; LUNG EMPHYSEMA; LUNG FIBROSIS; MALE; MIDDLE AGED; OXYGEN THERAPY; PATHOLOGY; PULMONARY HYPERTENSION; RADIOGRAPHY; SMOKING; COMPLICATION; HYPERTENSION, PULMONARY; PULMONARY EMPHYSEMA; PULMONARY FIBROSIS;

ACETYLCYSTEINE; AZATHIOPRINE; DISEASE MANAGEMENT; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MIDDLE AGED; OXYGEN INHALATION THERAPY; PHENYLPROPIONATES; PREDNISOLONE; PULMONARY EMPHYSEMA; PULMONARY FIBROSIS; PYRIDAZINES; SMOKING;

EID: 84876255842     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-S1-S2     Document Type: Article

References (17)

1. Lone cryptogenic fibrosing alveolitis: A functional-morphologic correlation based on extent of disease on thin-section computed tomography. Wells AU, King AD, Rubens MB, Cramer D, du Bois RM, Hansell DM, Am J Respir Crit Care Med 1997 155 1367 1375 10.1164/ajrccm.155.4.9105081 9105081
2. Idiopathic pulmonary fibrosis and emphysema: Decreased survival associated with severe pulmonary arterial hypertension. Mejia M, Carrillo G, Rojas-Serrano J, Estrada A, Suarez T, Alonso D, Barrientos E, Gaxiola M, Navarro C, Selman M, Chest 2009 136 10 15 10.1378/chest.08-2306 19225068
3. Pulmonary function measures predict mortality differently in ipf versus combined pulmonary fibrosis and emphysema. Schmidt SL, Nambiar AM, Tayob N, Sundaram B, Han MK, Gross BH, Kazerooni EA, Chughtai AR, Lagstein A, Myers JL, Murray S, Toews GB, Martinez FJ, Flaherty KR, Eur Respir J 2011 38 176 183 10.1183/09031936.00114010 21148225
4. Combined pulmonary fibrosis and emphysema: A distinct underrecognised entity. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, Israel-Biet D, Court-Fortune I, Valeyre D, Cordier JF, Eur Respir J 2005 26 586 593 10.1183/09031936.05.00021005 16204587
5. The syndrome of combined pulmonary fibrosis and emphysema. Cottin V, Cordier JF, Chest 2009 136 1 2 10.1378/chest.09-0538 19584202
6. Combined cryptogenic fibrosing alveolitis and emphysema: The value of high resolution computed tomography in assessment. Wiggins J, Strickland B, Turner-Warwick M, Respir Med 1990 84 365 369 10.1016/S0954-6111(08)80070-4 2247666
7. The presence of emphysema further impairs physiologic function in patients with idiopathic pulmonary fibrosis. Mura M, Zompatori M, Pacilli AM, Fasano L, Schiavina M, Fabbri M, Respir Care 2006 51 257 265 16533415
8. Acute exacerbations of idiopathic pulmonary fibrosis. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr., Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Muller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ, Am J Respir Crit Care Med 2007 176 636 643 10.1164/rccm.200703- 463PP 17585107
9. Usual interstitial pneumonia and nonspecific interstitial pneumonia with and without concurrent emphysema: Thin-section ct findings. Akira M, Inoue Y, Kitaichi M, Yamamoto S, Arai T, Toyokawa K, Radiology 2009 251 271 279 10.1148/radiol.2511080917 19221055
10. HRCT and histopathological evaluation of fibrosis and tissue destruction in ipf associated with pulmonary emphysema. Rogliani P, Mura M, Mattia P, Ferlosio A, Farinelli G, Mariotta S, Graziano P, Pezzuto G, Ricci A, Saltini C, Orlandi A, Respir Med 2008 102 1753 1761 10.1016/j.rmed.2008.07.010 18723334
11. Non-specific interstitial pneumonia in cigarette smokers: A ct study. Marten K, Milne D, Antoniou KM, Nicholson AG, Tennant RC, Hansel TT, Wells AU, Hansell DM, Eur Radiol 2009 19214521
12. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Akagi T, Matsumoto T, Harada T, Tanaka M, Kuraki T, Fujita M, Watanabe K, Respir Med 2009 103 1209 1215 10.1016/j.rmed.2009.02.001 19251407
13. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Cottin V, Le Pavec J, Prevot G, Mal H, Humbert M, Simonneau G, Cordier JF, Eur Respir J 2010 35 105 111 10.1183/09031936.00038709 19643948
14. Centrilobular emphysema combined with pulmonary fibrosis results in improved survival. Todd NW, Jeudy J, Lavania S, Franks TJ, Galvin JR, Deepak J, Britt EJ, Atamas SP, Fibrogenesis Tissue Repair 2011 4 6 10.1186/1755-1536-4-6 21324139
15. Idiopathic pulmonary fibrosis: A composite physiologic index derived from disease extent observed by computed tomography. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, Colby TV, du Bois RM, Hansell DM, Am J Respir Crit Care Med 2003 167 962 969 10.1164/rccm.2111053 12663338
16. Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: Case report and review of the literature. Mercurio V, Carlomagno G, Fazio S, Heart Lung 2012 22054725
17. "Triple therapy" in idiopathic pulmonary fibrosis: An alarming press release? Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Eur Respir J 2012 39 805 806 10.1183/09031936.00009112 22467722